Severe Hypocalcemia Risk w/Denosumab and CKD Patients On 1/19 the FDA issued a Drug Safety Communication about the risk of severe hypocalcemia in CKD patients taking denosumab for osteoporosis. https://t.co/VPpIZBZQkm https://t.co/yxFYn1ob5A